- Home
- ATOS vs BDTX Comparison
ATOS vs BDTX Comparison
Compare ATOS & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- BDTX
- Stock Information
- Founded
- ATOS 2009
- BDTX 2014
- Country
- ATOS United States
- BDTX United States
- Employees
- ATOS N/A
- BDTX N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATOS Health Care
- BDTX Health Care
- Exchange
- ATOS Nasdaq
- BDTX Nasdaq
- Market Cap
- ATOS 174.8M
- BDTX 161.6M
- IPO Year
- ATOS 2012
- BDTX 2020
- Fundamental
- Price
- ATOS $1.54
- BDTX $3.21
- Analyst Decision
- ATOS Strong Buy
- BDTX Strong Buy
- Analyst Count
- ATOS 3
- BDTX 4
- Target Price
- ATOS $6.25
- BDTX $15.50
- AVG Volume (30 Days)
- ATOS 502.2K
- BDTX 646.0K
- Earning Date
- ATOS 11-19-2024
- BDTX 11-05-2024
- Dividend Yield
- ATOS N/A
- BDTX N/A
- EPS Growth
- ATOS N/A
- BDTX N/A
- EPS
- ATOS N/A
- BDTX N/A
- Revenue
- ATOS N/A
- BDTX N/A
- Revenue This Year
- ATOS N/A
- BDTX N/A
- Revenue Next Year
- ATOS N/A
- BDTX N/A
- P/E Ratio
- ATOS N/A
- BDTX N/A
- Revenue Growth
- ATOS N/A
- BDTX N/A
- 52 Week Low
- ATOS $0.62
- BDTX $1.75
- 52 Week High
- ATOS $2.31
- BDTX $7.66
- Technical
- Relative Strength Index (RSI)
- ATOS 65.98
- BDTX 50.63
- Support Level
- ATOS $1.36
- BDTX $3.16
- Resistance Level
- ATOS $1.66
- BDTX $3.43
- Average True Range (ATR)
- ATOS 0.07
- BDTX 0.19
- MACD
- ATOS 0.02
- BDTX 0.12
- Stochastic Oscillator
- ATOS 80.65
- BDTX 98.56
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.